Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 709

1.

Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials.

Emamikia S, Arkema EV, Györi N, Detert J, Chatzidionysiou K, Dougados M, Burmester GR, van Vollenhoven R.

RMD Open. 2016 Sep 6;2(2):e000323. doi: 10.1136/rmdopen-2016-000323. eCollection 2016.

2.

Immunological characterization of the early human fracture hematoma.

Hoff P, Gaber T, Strehl C, Schmidt-Bleek K, Lang A, Huscher D, Burmester GR, Schmidmaier G, Perka C, Duda GN, Buttgereit F.

Immunol Res. 2016 Sep 14. [Epub ahead of print]

PMID:
27629117
3.

Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From Two Randomized Controlled Trials: SUMMACTA and BREVACTA.

Abdallah H, Hsu JC, Lu P, Fettner S, Zhang X, Douglass W, Bao M, Rowell L, Burmester GR, Kivitz A.

J Clin Pharmacol. 2016 Sep 7. doi: 10.1002/jcph.826. [Epub ahead of print]

PMID:
27599663
4.

The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016.

Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, Bathon JM, Buch MH, Burmester GR, Dougados M, Kay J, Mariette X, Breedveld FC, Kalden JR, Smolen JS, Furst DE.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98):69-76. Epub 2016 Aug 3. Review.

5.

Targeting GM-CSF in rheumatoid arthritis.

Avci AB, Feist E, Burmester GR.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98):39-44. Epub 2016 Jul 21. Review.

6.

Genomic stratification by expression of HLA-DRB4 alleles identifies differential innate and adaptive immune transcriptional patterns - A strategy to detect predictors of methotrexate response in early rheumatoid arthritis.

Stuhlmüller B, Mans K, Tandon N, Bonin MO, Smiljanovic B, Sörensen TA, Schendel P, Martus P, Listing J, Detert J, Backhaus M, Neumann T, Winchester RJ, Burmester GR, Häupl T.

Clin Immunol. 2016 Aug 26;171:50-61. doi: 10.1016/j.clim.2016.08.013. [Epub ahead of print]

PMID:
27570220
7.

A prospective pilot study to evaluate an animated home-based physical exercise program as a treatment option for patients with rheumatoid arthritis.

Zernicke J, Kedor C, Müller A, Burmester GR, Reißhauer A, Feist E.

BMC Musculoskelet Disord. 2016 Aug 18;17(1):351. doi: 10.1186/s12891-016-1208-3.

8.

Long-term follow-up of fertility and pregnancy in autoimmune diseases after autologous haematopoietic stem cell transplantation.

Massenkeil G, Alexander T, Rosen O, Dörken B, Burmester G, Radbruch A, Hiepe F, Arnold R.

Rheumatol Int. 2016 Aug 13. [Epub ahead of print]

PMID:
27522225
9.

Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers.

Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, Heijde Dv, Vollenhoven Rv, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME.

Ann Rheum Dis. 2016 Oct;75(10):e69. doi: 10.1136/annrheumdis-2016-210083. Epub 2016 Aug 12. No abstract available.

PMID:
27519773
10.

Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction.

Baraliakos X, Heldmann F, van den Bosch F, Burmester G, Gaston H, van der Horst-Bruinsma IE, Krause A, Schmidt R, Schneider M, Sieper J, Andermann B, van Tubergen A, Witt M, Braun J.

RMD Open. 2016 Jul 19;2(2):e000272. doi: 10.1136/rmdopen-2016-000272. eCollection 2016.

11.

The proteasome - victim or culprit in autoimmunity.

Feist E, Burmester GR, Krüger E.

Clin Immunol. 2016 Jul 27. pii: S1521-6616(16)30212-1. doi: 10.1016/j.clim.2016.07.018. [Epub ahead of print]

PMID:
27475228
12.

A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.

Kedor C, Zernicke J, Hagemann A, Gamboa LM, Callhoff J, Burmester GR, Feist E.

Clin Rheumatol. 2016 Sep;35(9):2203-10. doi: 10.1007/s10067-016-3360-4. Epub 2016 Jul 28.

PMID:
27470087
13.

Sustained Increase of 25-Hydroxyvitamin D Levels in Healthy Young Women during Wintertime after Three Suberythemal UV Irradiations-The MUVY Pilot Study.

Biersack MG, Hajdukiewicz M, Uebelhack R, Franke L, Piazena H, Klaus P, Höhne-Zimmer V, Braun T, Buttgereit F, Burmester GR, Detert J.

PLoS One. 2016 Jul 19;11(7):e0159040. doi: 10.1371/journal.pone.0159040. eCollection 2016.

14.

A Randomized Phase 2b Study of ABT-494, a Selective JAK1 Inhibitor in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate.

Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S.

Arthritis Rheumatol. 2016 Jul 7. doi: 10.1002/art.39808. [Epub ahead of print]

PMID:
27390150
15.

Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis.

Detert J, Dziurla R, Hoff P, Gaber T, Klaus P, Bastian H, Braun T, Schellmann S, Penzel T, Fietze I, Loeschmann PA, Jaehnig P, Straub RH, Burmester GR, Buttgereit F.

Clin Exp Rheumatol. 2016 Jun 22. [Epub ahead of print]

PMID:
27385076
16.

Rheumatoid arthritis: Glucocorticoid therapy and body composition.

Buttgereit F, Burmester GR.

Nat Rev Rheumatol. 2016 Aug;12(8):444-5. doi: 10.1038/nrrheum.2016.114. Epub 2016 Jul 7. No abstract available.

PMID:
27383915
17.

[Treat to target and personalized medicine (precision medicine)].

Detert J, Burmester GR.

Z Rheumatol. 2016 Aug;75(6):624-32. doi: 10.1007/s00393-016-0137-8. German. No abstract available.

PMID:
27365026
18.

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis.

Burmester GR, Landewé R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP.

Ann Rheum Dis. 2016 Jun 23. pii: annrheumdis-2016-209322. doi: 10.1136/annrheumdis-2016-209322. [Epub ahead of print]

19.

Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.

Schett G, Emery P, Tanaka Y, Burmester G, Pisetsky DS, Naredo E, Fautrel B, van Vollenhoven R.

Ann Rheum Dis. 2016 Aug;75(8):1428-37. doi: 10.1136/annrheumdis-2016-209201. Epub 2016 Jun 3. Review.

PMID:
27261493
20.

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.

Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME.

Ann Rheum Dis. 2016 May 10. pii: annrheumdis-2015-209057. doi: 10.1136/annrheumdis-2015-209057. [Epub ahead of print]

Items per page

Supplemental Content

Loading ...
Write to the Help Desk